Your Cart Is Empty!
Global Markets Directs, Hypertension - Pipeline Review, H2 2015, provides an overview of the Hypertensions therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Ache Laboratorios Farmaceuticos S/A
Afferent Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Anacor Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc.
Asahi Kasei Pharma Corp.
Ascendis Pharma A/S
Bial - Portela & Ca, S.A.
Biolab Sanus Farmaceutica Ltda.
Cardioxyl Pharmaceuticals, Inc.
Carolus Therapeutics, Inc.
China Grand Wuhan General Pharmaceutical Research Institute
Chong Kun Dang Pharmaceutical Corp.
CJ HealthCare Corp.
Conatus Pharmaceuticals Inc.
Corridor Pharmaceuticals Inc.
Daewoong Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
Dong-A Socio Group
Eli Lilly and Company
Esperion Therapeutics, Inc.
Galectin Therapeutics, Inc.
Gilead Sciences, Inc.
Glenveigh Medical, LLC
HanAll Biopharma Co., Ltd.
Hanmi Pharmaceuticals, Co. Ltd.
Intercept Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Jeil Pharmaceutical Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Jiangsu Hengrui Medicine Co., Ltd.
JW Pharmaceutical Corporation
Kowa Company, Ltd.
Lees Pharmaceutical Holdings Limited
Les Laboratoires Servier SAS
LG Life Science LTD.
Lotus Pharmaceutical Co., Ltd.
LTT Bio-Pharma Co., Ltd.
Merck & Co., Inc.
Mezzion Pharma Co. Ltd.
miRagen Therapeutics, Inc.
Mitsubishi Tanabe Pharma Corporation
Neurim Pharmaceuticals Ltd
Nippon Kayaku Co., Ltd.
Nippon Shinyaku Co., Ltd.
Ono Pharmaceutical Co., Ltd.
Peloton Therapeutics, Inc.
PhaseBio Pharmaceuticals, Inc.
Pluristem Therapeutics Inc.
Proteo, Inc. (Inactive)
Quantum Genomics SA
Reata Pharmaceuticals, Inc.
RedHill Biopharma Ltd.
Respira Therapeutics, Inc.
rEVO Biologics, Inc.
Selten Pharma, Inc
Sihuan Pharmaceutical Holdings Group Ltd.
Silence Therapeutics Plc
Simcere Pharmaceutical Group
Sinoxa Pharma GmbH
SteadyMed Therapeutics, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Sun Pharma Advanced Research Company Ltd.
Takeda Pharmaceutical Company Limited
The Medicines Company
Theravance Biopharma, Inc.
Toray Industries, Inc.
Torrent Pharmaceuticals Limited
TSH Biopharm Corporation Limited
Vectura Group Plc
VG Life Sciences, Inc.
Vicore Pharma AB
Following are different modes of Licenses.
a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.
b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.
c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.
1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :
a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]
b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]
2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:
a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.